Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05901974

Venetoclax Combined With Azactidine in the Treatment of ALAL

Acute Leukemia of Ambiguous Lineage Clinical Trial

Official title:
A Multicenter Prospective Clinical Study of Venetoclax Combined With Azactidine in the Treatment of Acute Leukaemias of Ambiguous Lineage

Clinical Trial Summary

The prognosis of acute leukaemias of ambiguous lineage is poor. The effect of chemotherapy regimen and hematopoietic stem cell transplantation are still unclear. Therefore, we will explore new therapy to improve the remission rate of acute leukaemias of ambiguous lineage. Venetoclax can significantly improve the remission rate and prolong PFS and OS. At present, venetoclax combined with azacitidine or decitabine has become the preferred treatment regimen for elderly AML patients. It also shows a high response rate in relapsed/refractory AML or MDS patients. There are few clinical studies on the treatment of ALAL. The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine in the treatment of newly diagnosed ALAL patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Acute Leukemia of Ambiguous Lineage
  • Leukemia
Clinical Trial Details
NCT number NCT05901974
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Sheng-Li Xue, MD
Phone 0086-0512-67781139
Email slxue@suda.edu.cn
Status Recruiting
Phase Phase 2
Start date July 1, 2021
Completion date July 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT02135874 - Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Phase 2
Recruiting NCT04065399 - A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Phase 1/Phase 2
Recruiting NCT05292664 - Venetoclax Basket Trial for High Risk Hematologic Malignancies Phase 1
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Not yet recruiting NCT04440267 - Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage Phase 2
Recruiting NCT06013423 - Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Phase 2
Not yet recruiting NCT06317662 - Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Phase 2
Active, not recruiting NCT02220985 - Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Phase 2
Completed NCT03012672 - Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Phase 2
Not yet recruiting NCT05521087 - A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Phase 1
Terminated NCT01701323 - Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03779854 - Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Phase 2
Recruiting NCT06177067 - Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT06355583 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial Phase 2
Completed NCT01858740 - Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Phase 2
Active, not recruiting NCT02828358 - Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Phase 2